8-K: Spero Therapeutics Announces Q2 2024 Results and Provides Business Update, Including Key Clinical Trial Milestones

Spero Therapeutics reported its second quarter 2024 financial results and provided a business update, highlighting the completion of enrollment in a Phase 2a trial for SPR720 and progress in the Phase 3 trial for tebipenem HBr.

Summary

• Spero Therapeutics announced its second quarter 2024 financial results, reporting a net loss of $17.9 million, or ($0.33) per share, compared to a net loss of $11.9 million, or ($0.23) per share, for the same period in 2023.
• Total revenue for the quarter was $10.2 million, up from $2.7 million in the second quarter of 2023, primarily due to increased collaboration revenue from the GSK agreement for tebipenem HBr and increased grant revenue related to the BARDA contract.
• Research and development expenses increased to $23.7 million from $9.5 million year-over-year, driven by costs associated with the Phase 3 trial for tebipenem HBr and the Phase 2a trial for SPR720.
• The company's cash balance was $63.5 million as of June 30, 2024, and they expect this, along with other non-dilutive funding, to support operations into late 2025.
• Enrollment has concluded in the Phase 2a proof-of-concept clinical trial for SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD), with preliminary data expected in the fourth quarter of 2024.
• The company is on track with enrollment in the global Phase 3 PIVOT-PO clinical trial for tebipenem HBr, with completion expected in the second half of 2025.
• Spero announced the departure of its Chief Medical Officer, Kamal Hamed, and appointed John C. Pottage, Jr., as Special Advisor to oversee the medical function while a search for a new CMO is underway.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and revenue growth, but tempered by the increased net loss and the departure of the CMO. The company's cash runway is a positive, but the need for future funding is a concern.

Positives

• Spero's revenue increased significantly year-over-year, driven by collaboration and grant revenue.
• The company has a solid cash position of $63.5 million, expected to fund operations into late 2025.
• Enrollment completion in the SPR720 Phase 2a trial is a positive milestone, with data expected soon.
• The Phase 3 trial for tebipenem HBr is progressing as planned.
• The appointment of John C. Pottage, Jr., as Special Advisor provides experienced oversight of the medical function.
• The company has a diversified clinical-stage portfolio with multiple assets in development.

Negatives

• Spero reported a net loss of $17.9 million for the second quarter of 2024, an increase from the $11.9 million loss in the same period of 2023.
• Research and development expenses have increased significantly year-over-year.
• The departure of the Chief Medical Officer creates a leadership gap.
• The Phase 2 trial for SPR206 is contingent on securing non-dilutive funding.

Risks

• The company's financial performance is subject to the risks associated with clinical trials, regulatory approvals, and commercialization of its product candidates.
• Spero is dependent on raising additional capital to fund its operations.
• There are risks associated with the reliance on third parties for manufacturing, development, and commercialization.
• The company faces competition from other pharmaceutical companies developing treatments for similar indications.
• The success of clinical trials is not guaranteed, and results may not be indicative of future outcomes.
• Regulatory approvals may be delayed or not granted, impacting the commercial prospects of the company's product candidates.

Future Outlook

Spero expects its cash and cash equivalents, along with other non-dilutive funding, to be sufficient to fund its operating expenses and capital expenditure requirements into late 2025. The company anticipates reporting preliminary data from the SPR720 Phase 2a trial and topline results from two Phase 1 studies in 4Q 2024. Enrollment in the tebipenem HBr Phase 3 trial is expected to complete in the second half of 2025.

Management Comments

• Sath Shukla, President and Chief Executive Officer of Spero, stated that the company's pipeline continues to advance as planned.
• Mr. Shukla expressed hope that SPR720 and Tebipenem could become meaningfully differentiated treatment options for patients.
• Mr. Shukla thanked Kamal Hamed for his contributions and expressed confidence in Dr. Pottage's oversight of the clinical programs.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on developing new treatments for infectious diseases, particularly those caused by multi-drug resistant bacteria. Spero's focus on novel treatments for rare diseases and MDR bacterial infections aligns with this trend. The company's progress in clinical trials and partnerships with companies like GSK are significant in this context.

Comparison to Industry Standards

• Spero's focus on oral antibiotics like tebipenem HBr aligns with a broader industry trend to move away from intravenous treatments, which can be more costly and require hospitalization. Companies like Achaogen (now defunct) and Paratek Pharmaceuticals have also pursued oral antibiotics for serious infections, but Spero's approach with a carbapenem is unique.
• The development of SPR720 for NTM-PD is notable as there are limited approved first-line therapies for this condition. Insmed's Arikayce is an inhaled treatment for NTM-PD, making Spero's oral approach a potential differentiator.
• The Phase 3 trial for tebipenem HBr is a large, global study, which is typical for late-stage drug development. The trial's design, including the use of a non-inferiority endpoint, is consistent with regulatory requirements for antibiotic approvals.
• Spero's financial results, while showing increased revenue, also highlight the high costs associated with drug development, which is common in the biopharmaceutical industry. The company's cash runway into late 2025 is a positive sign, but continued funding will be necessary.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the revenue growth and clinical trial progress.
• Employees may experience uncertainty due to the leadership transition but benefit from the company's continued operations.
• Patients may benefit from the potential development of new treatments for NTM-PD and cUTI.
• Partners like GSK may be encouraged by the progress of the tebipenem HBr program.

Next Steps

• Spero will present new SPR720 in-vitro resistance data at the IDWeek 2024 conference in October.
• The company expects to report preliminary data from the Phase 2a trial of SPR720 in 4Q 2024.
• Topline results from two Phase 1 clinical studies evaluating SPR720 are also expected in 4Q 2024.
• Spero will continue enrollment in the Phase 3 PIVOT-PO trial for tebipenem HBr, with completion expected in the second half of 2025.
• The company will continue its search for a new Chief Medical Officer.

Key Dates

Keywords

Spero Therapeutics, SPR720, Tebipenem HBr, SPR206, NTM-PD, cUTI, Clinical Trials, Phase 2a, Phase 3, Antibiotics, Infectious Diseases, Biopharmaceutical, Drug Development, Financial Results